Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.67 |
| ▸ | PYGM | P11217 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1469838 | 1.00 | TK1 (0.67) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL4977332 | 1.00 | TK1 (0.67) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL1469822 | 0.85 | TK1 (0.52) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL8296296 | 0.85 | TK1 (0.52) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL1469823 | 0.85 | TK1 (0.52) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL8907771 | 0.84 | TK1 (0.57) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL8292256 | 0.83 | TK1 (0.70) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Idoxuridine SCHEMBL9951400 | 0.80 | TK1 (1.00) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| Idoxuridine SCHEMBL37714 | 0.80 | TK1 (1.00) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| Idoxuridine SCHEMBL13252710 | 0.80 | TK1 (1.00) | TK1PYGMLMNASMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| WO-2005049582-A1 | METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | RNGTT, TYMP, SLC29A1 | TK1 17/4885PYGM 858/4885LMNA 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.